Poliovirus type 2 antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Poliovirus type 2 antigen (formaldehyde inactivated)
Accession Number
DB10796
Description

Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were grown from a continuous line of monkey kidney cells.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Inactivated poliomyelitis vaccine (D.C.O.) type 2 MEF1
  • Inactivated poliovirus type II
  • poliovirus vaccine inactivated, type 2 (MEF-1)

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Imovax PolioPoliovirus type 2 antigen (formaldehyde inactivated) (8 unit/7mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 unit/7mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 unit/7mL)SuspensionSubcutaneousSanofi Pasteur Limited2007-03-22Not applicableCanada flag
Infanrix HexaPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
Infanrix HexaPoliovirus type 2 antigen (formaldehyde inactivated) (8 DU/0.5ml) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 µg/0.5ml) + Bordetella pertussis pertactin antigen (8 µg/0.5ml) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (40 IU/0.5ml) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (30 IU/0.5ml) + Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (10 µg/0.5ml) + Hepatitis B Vaccine (Recombinant) (10 µg/0.5ml) + Pertussis vaccine (25 µg/0.5ml) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 DU/0.5ml) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 DU/0.5ml)InjectionIntramuscularGlaxo Smith Kline Biologicals S.A.2021-02-10Not applicableEU flag
IpolPoliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.1990-12-21Not applicableUS flag
IpolPoliovirus type 2 antigen (formaldehyde inactivated) (8 [D'ag'U]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [D'ag'U]/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions1990-12-21Not applicableUS flag
KinrixPoliovirus type 2 antigen (formaldehyde inactivated) (8 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 [iU]/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 [iU]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 [iU]/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [iU]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [iU]/0.5mL)Injection, suspensionIntramuscularGlaxoSmithKline Biologicals SA2008-07-09Not applicableUS flag
PediarixPoliovirus type 2 antigen (formaldehyde inactivated) (8 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (25 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (25 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (10 [iU]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (25 [iU]/0.5mL) + Hepatitis B virus subtype ADW2 HBSAG surface protein antigen (10 ug/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (40 [iU]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (32 [iU]/0.5mL)Injection, suspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-24Not applicableUS flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
23JE9KDF4R
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910902
RxNav
763098

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1
4CompletedPreventionAcellular Pertussis / Diphtheria / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionDiphtheria / Haemophilus Influenzae Serotype b (Hib) / Meningitis / Meningococcal Infections / Pertussis / Tetanus1
4CompletedPreventionDrug Therapy, Combination / Fever, Chemically Induced / Infants / Vaccines, Pneumococcal1
4CompletedPreventionFlu caused by Influenza1
4CompletedPreventionPertussis1
4CompletedPreventionPoliomyelitis4
4CompletedPreventionStreptococcal Infections1
4CompletedPreventionVaccines, Pneumococcal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular2 Lf/0.5mL
Injection, suspensionIntramuscular5 ug/0.5mL
Injection, solutionIntramuscular8 mcg/0.5ml
SuspensionIntramuscular2 IU/0.5ml
Injection, suspensionIntramuscular8 mcg/0.5ml
Injection, suspensionIntramuscular20 UI
Injection, solutionIntramuscular20 IU
Injection, suspensionIntramuscular25 mcg/0.5ml
Injection, suspensionIntramuscular; Subcutaneous40 U
SuspensionSubcutaneous
Injection, suspensionIntramuscular; Subcutaneous40 [D'ag'U]/0.5mL
Injection
InjectionIntramuscular
Injection, powder, for suspensionIntramuscular25 mcg
Injection, powder, for suspensionIntramuscular30 UI
SuspensionIntramuscular30 UI
Injection, powder, for suspensionIntramuscular10 mcg
Injection, powder, for suspensionIntramuscular25 mcg/0.5ml
Injection, powder, for suspensionIntramuscular8 μg
Injection, suspensionIntramuscular40 [D'ag'U]/0.5mL
Injection, suspensionIntramuscular
Injection, powder, for suspensionIntramuscular30 IU/0.5ml
InjectionIntramuscular30 IU
Injection, suspensionIntramuscular2 IU
Injection, suspensionIntramuscular20 IU/0.5ml
Injection, suspensionIntramuscular2 IU/0.5ml
Injection, suspensionIntramuscular2 UI
Injection, suspensionIntramuscular30 UI
Injection, suspensionIntramuscular30 IU
Injection, suspensionIntramuscular30 IU/0.5mL
Injection, solutionIntramuscular40 D angtigen units
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:04 / Updated on June 12, 2020 16:53